Fosaprepitant

Generic Name: Fosaprepitant

Brand Names: Emend, Focinvez, Ivemend

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₂F_₇N_₄O_₆P

CAS Number: 172673-20-0

Unique Ingredient Identifier: 6L8OF9XRDC

Background: Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.

Indication: Fosaprepitant is indicated in adult and pediatric patients ≥6 months of age, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin. It is also indicated for the treatment of delayed nausea and vomiting with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Associated Conditions: Acute Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by moderately emetogenic chemotherapy

Clinical Trials

Granisetron Transdermal Patch for Prophylaxis of Delayed CINV

Phase 3

Conditions: Chemotherapy-induced Nausea and Vomiting (CINV)

Interventions: Drug: Granisetron transdermal patch
Drug: Palonosetron
Drug: Aprepitant
Drug: Fosaprepitant
Drug: Dexamethasone

First Posted Date: 2021-06-03

Last Posted Date: 2021-06-03

Lead Sponsor: Fudan University

Target Recruit Count: 140

Registration Number: NCT04912271

Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients

Not Applicable

Conditions: Chemotherapy Induced Nausea and Vomiting
Pediatric Cancer Patients

Interventions: Drug: fosaprepitant
Drug: aprepitant
Drug: Granisetron plus dexamethasone

First Posted Date: 2021-05-05

Last Posted Date: 2021-05-10

Lead Sponsor: Shanghai Children's Medical Center

Target Recruit Count: 120

Registration Number: NCT04873284

Locations: 🇨🇳
Shanghai Children's Medical Center, Shanghai, China

Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery

Phase 3

Completed

Conditions: C.Surgical Procedure; Gastrointestinal

Interventions: Drug: palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl
Drug: palonosetron, dexamethasone, and 0.9% NaCl

First Posted Date: 2021-04-21

Last Posted Date: 2022-12-29

Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Target Recruit Count: 1154

Registration Number: NCT04853147

Locations: 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Phase 1

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: fosaprepitant

First Posted Date: 2020-11-19

Last Posted Date: 2022-11-07

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 100

Registration Number: NCT04636632

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy

Phase 3

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Emend® (Aprepitant)
Drug: Zyprexa® (OLANZapine 5MG)

First Posted Date: 2019-09-03

Last Posted Date: 2020-08-19

Lead Sponsor: CR-CSSS Champlain-Charles-Le Moyne

Target Recruit Count: 30

Registration Number: NCT04075955

Locations: 🇨🇦
Hôpital Charles-LeMoyne, Greenfield Park, Quebec, Canada

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Phase 4

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Fosaprepitant Dimeglumine
Drug: 5-HT3 antagonist
Drug: Dexamethasone

First Posted Date: 2019-08-13

Last Posted Date: 2025-01-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 103

Registration Number: NCT04054193

Locations: 🇺🇸
Children's Hospitals and Clinics of Minnesota ( Site 1109), Minneapolis, Minnesota, United States
🇵🇪
Instituto Nacional de Enfermedades Neoplasicas ( Site 1502), Lima, Peru
🇺🇸
Phoenix Childrens Hospital ( Site 1101), Phoenix, Arizona, United States

and more 23 locations

PALONOSETRON X FOSAPREPITANT IN PONV

Phase 4

Conditions: Nausea and Vomiting, Postoperative

Interventions: Drug: Palonosetron
Drug: Fosaprepitant

First Posted Date: 2018-07-16

Last Posted Date: 2019-03-12

Lead Sponsor: Hospital Federal de Bonsucesso

Target Recruit Count: 100

Registration Number: NCT03586817

Locations: 🇧🇷
Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Phase 3

Completed

Conditions: Malignant Neoplasm

Interventions: Drug: Palonosetron Hydrochloride
Drug: Ondansetron Hydrochloride
Drug: Dexamethasone
Drug: Fosaprepitant Dimeglumine
Other: Placebo
Drug: Olanzapine

First Posted Date: 2018-07-05

Last Posted Date: 2025-04-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 690

Registration Number: NCT03578081

Locations: 🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸
Hurley Medical Center, Flint, Michigan, United States
🇺🇸
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States

and more 562 locations